CN105395925A - Composition with hypotensive and anti-obesity effects based on blood fat reduction - Google Patents

Composition with hypotensive and anti-obesity effects based on blood fat reduction Download PDF

Info

Publication number
CN105395925A
CN105395925A CN201510845072.0A CN201510845072A CN105395925A CN 105395925 A CN105395925 A CN 105395925A CN 201510845072 A CN201510845072 A CN 201510845072A CN 105395925 A CN105395925 A CN 105395925A
Authority
CN
China
Prior art keywords
parts
composition
weight
lecithin
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510845072.0A
Other languages
Chinese (zh)
Inventor
叶丽芳
朱妙飞
吕晓霞
毛岳忠
高靳磊
易超宇
留梦甜
居雪峰
李丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HANGZHOU NEPTUNUS BIOENGINEERING CO Ltd
Original Assignee
HANGZHOU NEPTUNUS BIOENGINEERING CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANGZHOU NEPTUNUS BIOENGINEERING CO Ltd filed Critical HANGZHOU NEPTUNUS BIOENGINEERING CO Ltd
Priority to CN201510845072.0A priority Critical patent/CN105395925A/en
Publication of CN105395925A publication Critical patent/CN105395925A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention belongs to the field of nutrition and health care and relates to a composition with the hypotensive and anti-obesity effects based on blood fat reduction. The composition is prepared from soybean lecithin, lecithin, eicosapentaenoic acid (EPA), docosahexenoic acid (DNA), conjugated linoleic acid, a white kidney bean extract, dietary fiber, red rice, resveratrol, coenzyme Q10 and a vitamin E. According to the composition, on the basis of modern nutriology, phospholipids, unsaturated fatty acid, natural plant extracts and oxidation resistance functional components are combined, the blood vessel waste is removed, blood fat reduction is used as the functional basis, and then the hypotensive and anti-obesity effects are achieved.

Description

A composition based on blood lipid reducing and having blood pressure lowering and weight reducing effects
Technical Field
The invention relates to the field of nutrition and health care, in particular to a composition with blood pressure lowering and weight losing effects based on blood fat reduction.
Background
With the development of society and the improvement of living standard of human beings, the dietary structure of people is greatly changed, and the change from the intake of multiple vegetables to the intake of multiple meats is carried out. Further, due to the nature of work and the intense pace of life, people are mostly seated and working, and lack exercise for a long time. This lifestyle causes people to ingest excessive calories and store them in the body, which has been known to cause obesity, hyperlipidemia and hypertension for a long time.
Scientific studies have shown that obesity, hyperlipidemia and hypertension are the biggest causes of cardiovascular diseases. Cardiovascular diseases (including cerebrovascular diseases) are statistically the first cause of death in the world today. According to the world health organization, about 1700 thousands of people die of the chronic disease annually, accounting for about 30% of the total death worldwide. That is, one of every 3 deaths is due to cardiovascular disease. In addition, since the body is in an obese state for a long time, the islets of langerhans of the human body are also damaged, and there is a high possibility that type II diabetes will be caused.
In conclusion, the symptoms of obesity, hyperlipidemia and hypertension seriously affect the quality of life and harm human health. At present, products aiming at symptoms of obesity, hyperlipidemia and hypertension in the market mainly comprise two types of health-care food and medicine:
(1) the health food is mainly prepared from single or less than four compound preparations of raw materials such as L-carnitine, unsaturated fatty acid and the like, mainly aims at one of symptoms of obesity, hyperlipidemia and hypertension, and has single effect.
(2) Drugs mainly include statins and angiotensin inhibitors, and although they have a significant effect, they are highly harmful to the organs and nervous system of the body and are therefore of low safety.
Disclosure of Invention
In view of the above, the present invention provides a composition with blood pressure lowering and weight reducing effects based on blood fat reduction, which combines four functional components, namely phospholipids, unsaturated fatty acids, natural plant extracts and antioxidants, according to modern nutriology, so as to remove blood vessel wastes and reduce blood fat, thereby achieving the effects of blood pressure lowering and weight reducing.
In order to achieve the purpose, the invention provides the following technical scheme:
a composition based on blood lipid lowering and having blood pressure lowering and weight reducing effects is prepared from soybean phospholipid, lecithin, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acid, semen Phaseoli vulgaris extract, dietary fiber, red rice, resveratrol, and coenzyme Q10And vitamin E.
Further, the composition comprises 3000 parts by weight of soybean phospholipid 1000-101-3 parts of vitamin E10-20 parts of vitamin E.
Wherein,
(1) the soybean phospholipid and the lecithin belong to phospholipid substances, can inhibit the absorption of cholesterol in intestinal tracts, and can clean and reduce the cholesterol deposited in blood vessels;
(2) EPA, DHA and conjugated linoleic acid belong to unsaturated fatty acid substances, and can reduce the contents of cholesterol and triglyceride in blood, control the concentration of blood fat and improve the content of high-density lipoprotein;
(3) the white kidney bean extract, the dietary fiber, the red yeast rice, the resveratrol and other plant extracts can regulate the energy metabolism in vivo and reduce blood fat and blood pressure.
(4) Coenzyme Q10Vitamin E belongs to antioxidant substances and can effectively protect other functional components from being oxidized and ineffective.
The effects of the above four aspects are mutually cooperated and act on a human body together, and by taking the composition disclosed by the invention, the energy metabolism of the human body can be effectively regulated, redundant fat and cholesterol are eliminated, and blood fat is reduced, so that the effects of reducing blood pressure and losing weight are further achieved.
The best technical scheme of the composition is as follows:
a composition with blood pressure lowering and weight losing effects based on blood fat reduction comprises the following components in parts by weight: 2000 parts of soybean lecithin, 300 parts of EPA (eicosapentaenoic acid), 300 parts of DHA (docosahexaenoic acid), 1200 parts of conjugated linoleic acid, 400 parts of white kidney bean extract, 400 parts of dietary fiber, 35 parts of red yeast rice, 35 parts of resveratrol and coenzyme Q102 parts of vitamin E15 parts.
Further, the composition is prepared by the following steps:
step 1, red yeast rice, resveratrol and coenzyme Q10Mixing vitamin E to obtain mixture 1;
step 2, uniformly mixing the mixture 1 with lecithin, EPA, DHA, white kidney bean extract and dietary fiber to obtain a mixture 2;
and 3, uniformly mixing the mixture 3 with the soybean lecithin and the conjugated linoleic acid to obtain the soybean lecithin-conjugated linoleic acid.
The invention has the following advantages and beneficial effects:
(1) the composition has the effects of reducing blood lipid as functional basis, and effectively reducing in vivo excessive fat and cholesterol, thereby achieving the effects of clearing blood vessel, reducing blood lipid, lowering blood pressure and reducing weight.
(2) The composition contains a potent antioxidant substance, and is effective in preventing and preventing the loss of efficacy due to oxidation.
(3) Compared with the existing health food and pharmaceutical products, the composition has more diversified effects and higher safety.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The invention discloses a composition with blood pressure lowering and weight losing effects based on blood fat reduction, and the composition can be realized by appropriately improving parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the compositions of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, or appropriate variations and combinations thereof, may be made to practice and use the invention without departing from the spirit and scope of the invention.
In order to better illustrate the invention, reference will now be made to specific examples.
Example 1:
1. weighing the following raw materials in proportion: 3000g of soybean phospholipid, 400g of lecithin, 400g of EPA (eicosapentaenoic acid) 400g, 400g of DHA (docosahexaenoic acid), 1600g of conjugated linoleic acid, 500g of white kidney bean extract, 500g of dietary fiber, 50g of red yeast rice, 50g of resveratrol and coenzyme Q103g and vitamin E20 g.
2. Uniformly mixing red yeast rice, resveratrol, coenzyme Q10 and vitamin E to obtain a mixture 1;
3. uniformly mixing the mixture 1 with lecithin, EPA, DHA, white kidney bean extract and dietary fiber to obtain a mixture 2;
4. and uniformly mixing the mixture 3 with the soybean lecithin and the conjugated linoleic acid to obtain the soybean lecithin-conjugated linoleic acid.
Example 2:
1. weighing the following raw materials in proportion: 1000g of soybean phospholipid, 200g of lecithin, 200g of EPA200g, 200g of DHA, 800g of conjugated linoleic acid, 300g of white kidney bean extract, 300g of dietary fiber, 20g of red yeast rice, 20g of resveratrol and coenzyme Q101g and vitamin E10 g.
2. Uniformly mixing red yeast rice, resveratrol, coenzyme Q10 and vitamin E to obtain a mixture 1;
3. uniformly mixing the mixture 1 with lecithin, EPA, DHA, white kidney bean extract and dietary fiber to obtain a mixture 2;
4. and uniformly mixing the mixture 3 with the soybean lecithin and the conjugated linoleic acid to obtain the soybean lecithin-conjugated linoleic acid.
Example 3:
1. weighing the following raw materials in proportion: 2000g of soybean phospholipid, 300g of lecithin, 300g of EPA300g, 300g of DHA, 1200g of conjugated linoleic acid, 400g of white kidney bean extract, 400g of dietary fiber, 35g of red yeast rice, 35g of resveratrol and coenzyme Q102g and vitamin E15 g.
2. Uniformly mixing red yeast rice, resveratrol, coenzyme Q10 and vitamin E to obtain a mixture 1;
3. uniformly mixing the mixture 1 with lecithin, EPA, DHA, white kidney bean extract and dietary fiber to obtain a mixture 2;
4. and uniformly mixing the mixture 3 with the soybean lecithin and the conjugated linoleic acid to obtain the soybean lecithin-conjugated linoleic acid.
Example 4:
example 4 is a blood lipid lowering test of the compositions prepared in examples 1-3.
32 hyperlipidemia model mice were taken and randomly divided into 4 groups (1 control group and 3 example groups). Example groups rats were sacrificed after continuous feeding for 30 days according to a gavage composition of 0.2g/10g body weight, and Total Cholesterol (TC) and Triglyceride (TG) were measured, and the results are shown in the following table:
note:▲P<total Cholesterol (TC) was significantly different in 0.05, 3 example groups from the control group.
※P<Triglyceride (TG) was significantly different in 0.05, 3 example groups from the control group.
From the above results, it can be seen that the compositions prepared in examples 1 to 3 had the effect of reducing blood lipid.
Example 5:
example 5 is a blood pressure lowering test of the compositions prepared in examples 1-3.
32 essential hypertension rats were selected and randomly divided into 4 experimental groups (1 control group and 3 example groups), and after the example groups were fed with the gastric lavage composition at 1500mg/kg body weight for 30 days, blood pressure was measured, and the results are shown in the following table:
group of Blood pressure (mmHg)
Example 1 167.6±1.63▲
Example 2 164.2±1.59▲
Example 3 166.5±1.98▲
Control group 187.6±2.14▲
Note:▲P<the blood pressure of 0.05 and 3 example groups is significantly different from that of the control group.
As can be seen from the above results, the compositions prepared in examples 1 to 3 had the effect of lowering blood pressure.
Example 5:
example 5 is a weight loss test of the compositions prepared in examples 1-3.
32 obese model mice were selected and randomly divided into 4 experimental groups (1 control group and 3 example groups), and the example groups were fed with the gastric lavage composition at 400mg/kg body weight for 40 days. The results are shown in the following table:
group of Final weight (g) Body fat weight (g) Diameter of fat cell (μm)
Example 1 26.8±2.5▲ 0.445±0.131※ 31.03±2.16◆
Example 2 26.4±2.7▲ 0.458±0.195※ 31.15±1.79◆
Example 3 25.9±2.9▲ 0.439±0.204※ 30.54±1.85◆
Control group 38.5±3.6▲ 0.774±0.231※ 38.78±2.03◆
Note:▲P<the final weight of 0.05, 3 example groups was significantly different from the control group.
※P<The body fat weight of 0.05 and 3 example groups was significantly different from that of the control group.
◆P<The diameters of the fat cells of 0.05 and 3 example groups are significantly different from those of the control group.
From the above results, it can be seen that the compositions prepared in examples 1 to 3 had a slimming effect.
The foregoing is directed to embodiments of the present invention and it is understood that various modifications and enhancements may be made by those skilled in the art without departing from the principles of the invention, which should be considered as within the scope of the invention.

Claims (4)

1. A composition based on blood lipid lowering and having blood pressure lowering and weight reducing effects is prepared from soybean phospholipid, lecithin, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), conjugated linoleic acid, semen Phaseoli vulgaris extract, dietary fiber, red rice, resveratrol, and coenzyme Q10And vitamin E.
2. The composition as claimed in claim 1, wherein the composition comprises soy phosphorus in parts by weight3000 parts of lipid 1000-101-3 parts of vitamin E10-20 parts of vitamin E.
3. The composition as claimed in claim 1, wherein the composition comprises 2000 parts by weight of soybean phospholipids, 300 parts by weight of lecithin, 300 parts by weight of EPA, 300 parts by weight of DHA, 1200 parts by weight of conjugated linoleic acid, 400 parts by weight of navy bean extract, 400 parts by weight of dietary fibers, 35 parts by weight of red yeast rice, 35 parts by weight of resveratrol, and coenzyme Q102 parts of vitamin E15 parts.
4. The composition according to any one of claims 1 to 3, wherein the composition is prepared by the steps of:
step 1, red yeast rice, resveratrol and coenzyme Q10Mixing vitamin E to obtain mixture 1;
step 2, uniformly mixing the mixture 1 with lecithin, EPA, DHA, white kidney bean extract and dietary fiber to obtain a mixture 2;
and 3, uniformly mixing the mixture 3 with the soybean lecithin and the conjugated linoleic acid to obtain the soybean lecithin-conjugated linoleic acid.
CN201510845072.0A 2015-11-27 2015-11-27 Composition with hypotensive and anti-obesity effects based on blood fat reduction Pending CN105395925A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510845072.0A CN105395925A (en) 2015-11-27 2015-11-27 Composition with hypotensive and anti-obesity effects based on blood fat reduction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510845072.0A CN105395925A (en) 2015-11-27 2015-11-27 Composition with hypotensive and anti-obesity effects based on blood fat reduction

Publications (1)

Publication Number Publication Date
CN105395925A true CN105395925A (en) 2016-03-16

Family

ID=55461913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510845072.0A Pending CN105395925A (en) 2015-11-27 2015-11-27 Composition with hypotensive and anti-obesity effects based on blood fat reduction

Country Status (1)

Country Link
CN (1) CN105395925A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107484957A (en) * 2017-08-17 2017-12-19 威海烟墩角生物科技有限公司 A kind of lecithin red yeast rice particle electuary and method
CN107960662A (en) * 2017-11-03 2018-04-27 嘉必优生物技术（武汉）股份有限公司 A kind of health products with hypolipemic function and preparation method thereof
CN108450938A (en) * 2017-02-20 2018-08-28 广州小杉健康科技有限公司 A kind of fat reducing meal replacement powder and preparation method thereof
CN110935002A (en) * 2019-12-22 2020-03-31 重庆申高生化制药股份有限公司 Composition with blood pressure lowering effect and application thereof
CN112450436A (en) * 2020-11-24 2021-03-09 山东商业职业技术学院 Composition with function of improving cardiovascular function and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004222594A (en) * 2003-01-23 2004-08-12 Kao Corp Method for producing diglyceride
CN101611760A (en) * 2008-06-26 2009-12-30 威海清华紫光科技开发有限公司 The extraction of soybean lecithin and the production method of series of products thereof
CN101953856A (en) * 2009-07-14 2011-01-26 博辉生物药业(深圳)有限公司 Lecithin soft capsule
CN103517711A (en) * 2011-05-03 2014-01-15 希格马托制药工业公司 Composition useful for the treatment of lipid metabolism disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004222594A (en) * 2003-01-23 2004-08-12 Kao Corp Method for producing diglyceride
CN101611760A (en) * 2008-06-26 2009-12-30 威海清华紫光科技开发有限公司 The extraction of soybean lecithin and the production method of series of products thereof
CN101953856A (en) * 2009-07-14 2011-01-26 博辉生物药业(深圳)有限公司 Lecithin soft capsule
CN103517711A (en) * 2011-05-03 2014-01-15 希格马托制药工业公司 Composition useful for the treatment of lipid metabolism disorders

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
加百列: "《如何选择营养素》", 30 June 2009, 中国社会出版社 *
周广利等: "多烯酸乙酯胶丸治疗高脂血症36例", 《华北煤炭医学院学报》 *
啊蛇糯米团: "诺贝尔奖认证产品——辅酶Q10", 《HTTP://WWW.PAIGUZX.CN/A/748804/35911903.HTML》 *
杨秀芹等: "谷维素配合多烯康治疗高脂血症疗效观察", 《实用医技》 *
罗登林: "《小儿常见病食疗智慧》", 31 January 2013, 中国医药科技出版社 *
腾飞: "芸豆也能减肥了，白芸豆为什么能减肥", 《HTTP://BLOG.SINA.COM.CN/S/BLOG_AFDD6C5901015A5S.HTML》 *
蒋慕东: "《二十世纪中国大豆科技发展研究》", 31 August 2008, 中国三峡出版社 *
郑积源: "《科技新知辞典》", 31 July 2001, 京华出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108450938A (en) * 2017-02-20 2018-08-28 广州小杉健康科技有限公司 A kind of fat reducing meal replacement powder and preparation method thereof
CN107484957A (en) * 2017-08-17 2017-12-19 威海烟墩角生物科技有限公司 A kind of lecithin red yeast rice particle electuary and method
CN107960662A (en) * 2017-11-03 2018-04-27 嘉必优生物技术（武汉）股份有限公司 A kind of health products with hypolipemic function and preparation method thereof
CN110935002A (en) * 2019-12-22 2020-03-31 重庆申高生化制药股份有限公司 Composition with blood pressure lowering effect and application thereof
CN112450436A (en) * 2020-11-24 2021-03-09 山东商业职业技术学院 Composition with function of improving cardiovascular function and application

Similar Documents

Publication Publication Date Title
CN105395925A (en) Composition with hypotensive and anti-obesity effects based on blood fat reduction
Wasser Reishi or ling zhi (Ganoderma lucidum)
US8663704B2 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
CN102133384B (en) Ginger and dried orange peel composition, preparation method thereof and application of ginger and dried orange peel composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy
CN102145159B (en) Ginger and elecampane composition, preparation method of ginger and elecampane composition and use of ginger and elecampane composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy
CN102091315A (en) Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers
Alauddina et al. Rice bran as a functional food: An overview of the conversion of rice bran into a superfood/functional food
WO2008153426A1 (en) Anti-inflammatory composition and use thereof
CN102166338A (en) Alpinia katsumadai-ginger composite, preparation method thereof and use thereof for preparing toxicity-attenuating and effect-increasing medicine for radiotherapy and chemotherapy of cancer
GHASEMINASAB et al. A review on pistachio: Its composition and benefits regarding the prevention or treatment of diseases
Liu et al. Unsaturated fatty acids in natural edible resources, a systematic review of classification, resources, biosynthesis, biological activities and application
US10653655B2 (en) Composition for preventing or improving peripheral neuropathy
CN106858595A (en) One kind burn tailored version clinical nutrition formula and preparation method thereof
CN108294306A (en) A kind of full nutrition special medicine purposes formula food of amino acid pattern
CN102091314B (en) Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer
US20090142419A1 (en) Anti-inflammatory extract and agent and method for the production thereof
do Nascimento et al. Review on the potential application of non-phenolic compounds from native Latin American food byproducts in inflammatory bowel diseases
Chaouachi et al. A Review of the Health-Promoting Properties of Spirulina with a Focus on athletes’ Performance and Recovery
CN105705025B (en) Edible lipid composition comprising stearidonic acid and olive oil
CN102091313B (en) Composition of perilla leaf and ginger, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer
CN102552847B (en) Ginger and inula flower composition for reducing vomiting caused by cancer chemotherapy and increasing curative effect for chemotherapy and preparing method thereof
CN107372861B (en) Composition and application thereof in preparation of product for improving hyperlipidemia
Lee A flood of health functional foods: what is to be recommended?
CN108434358A (en) A kind of alimentation composition and its preparation method and application with neuroprotection
KR20190118556A (en) Omega-3 fatty acid composition for the prevention and / or treatment of cachexia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160316